Home > Insider Trading > Filing (0001127602-20-015191)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1682852	Moderna Inc.	MRNA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1443340	Stephane Bancel	C/O Moderna, Inc. 200 Technology Square Cambridge MA 02139	Chief Executive Officer	Yes	Yes	No	No

Transaction Summary

Sold:	28,442 shares	Avg. Price: $48.70	Total Value: $1,385,125.40
Number of Shares After Transactions:	9,206,279 shares

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-05-01	4,349	$48.70	6,688,429	No	4	S	Direct
Common Stock	Disposition	2020-05-01	11,046	$48.70	618,592	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-05-01	8,698	$48.70	7,900,003	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2020-05-01	4,349	$48.70	9,206,279	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/28/2018.
These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
This sale was effected pursuant to a Rule 10b5-1 trading plan.
These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.